8 source-based articles maintained by the HealthRX.com Editorial Team.
Showing 8 of 8 clinical reviews.
A guide to the FDA approval history, compounding legal status, labeling requirements, and safety profile of oral micronized progesterone (Prometrium and generics).
A clinical breakdown of oral micronized progesterone (Prometrium) FAERS safety signals, FDA post-market surveillance findings, label warnings, and what the adverse-event data mean for patients and prescribers.
Complete FDA approval history of oral micronized progesterone (Prometrium), including regulatory milestones, label updates, post-market safety data, and clinical trial evidence from PEPI through current guidelines.
A comprehensive review of FDA label changes for oral micronized progesterone (Prometrium) from 2020 through 2026, including safety updates, boxed warning revisions, and clinical implications for prescribers.
A clinical review of the oral micronized progesterone (Prometrium) regulatory history, current FDA-approved indications, post-market safety data, and next-generation progesterone delivery systems in development.
A clinical comparison of how the FDA and EMA regulate oral micronized progesterone (Prometrium/Utrogestan), including labeling differences, boxed warnings, and post-market safety data.
A comprehensive review of oral micronized progesterone (Prometrium) regulatory approvals worldwide, FDA labeling, safety data, and clinical evidence supporting its use in hormone therapy.
A clinical review of oral micronized progesterone (Prometrium) legal disputes, patent history, generic entry, FDA regulatory milestones, and post-market safety updates.